Experimental antibody IC14 tested in rare heart condition
Disease control
Completed
This early-phase trial tested IC14 (atibuclimab), an antibody that targets inflammation, in one person with arrhythmogenic cardiomyopathy (ACM), a rare heart muscle disease that can cause dangerous heart rhythms. The study measured safety, blood markers of inflammation, and heart…
Phase: PHASE1, PHASE2 • Sponsor: Implicit Bioscience • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC